ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ODX Omega Diagnostics Group Plc

2.20
0.00 (0.00%)
24 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.20 2.00 2.40 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Omega Diagnostics Group PLC Hardman Research: Food intolerance driving growth

29/11/2016 7:15am

RNS Non-Regulatory


TIDMODX

Omega Diagnostics Group PLC

29 November 2016

Hardman Research: Food intolerance driving growth

Food intolerance driving growth: Omega Diagnostics Group has an established core business providing high quality in vitro diagnostic tests within three core areas of competence - Food Intolerance, Allergy & Autoimmune, Infectious Disease - that are sold in over 100 countries. The group offers steady low single-digit growth which is profitable and cash generative. Investment in new products has seen the launch of a new panel of automated allergy tests and progress on Visitect for diagnosis of HIV. Given Omega's established position, the Board sees opportunities for an accelerated growth strategy.

Please click here for the full report:

http://www.hardmanandco.com/docs/default-source/company-docs/omega-diagnostics-group-plc-documents/29.11.16-food-intolerance-driving-growth.pdf

 
 To contact us:      Analysts: 
  Hardman & Co        Dr Martin Hall mh@hardmanandco.com 
  11/12 Tokenhouse    Dr Dorothea Hill dmh@hardmanandco.com 
  Yard                Dr Gregoire Pave gp@hardmanabdco.com 
  London              Telephone: +44 20 7929 3399 
  EC2R 7AS            Follow us on Twitter @HardmanandCo 
 

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEAXFPALDKFFF

(END) Dow Jones Newswires

November 29, 2016 02:15 ET (07:15 GMT)

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Your Recent History

Delayed Upgrade Clock